Canaccord lowered the firm’s price target on Orthofix (OFIX) to $20 from $24 and keeps a Buy rating on the shares. The firm updated its model to reflect Q4 results and 2026 guidance.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OFIX:
- Orthofix Medical: Strengthening Growth Momentum and Profitability Supports Compelling Buy-Rated Valuation
- Orthofix price target lowered to $17 from $18 at Barrington
- Orthofix reports Q4 EPS (6c) vs. (75c) last year
- Orthofix sees FY26 revenue $850M-$860M, consensus $862.76M
- Orthofix Posts Strong Q4 Results and Optimistic 2026 Outlook